Business context and reporting period
AN2 Therapeutics, Inc. filed its annual report for the fiscal year ended December 31, 2022. The clinical-stage biopharmaceutical company had no approved products and had generated no product revenue. Its lead candidate, epetraborole, was in a pivotal Phase 2/3 trial for treatment-refractory Mycobacterium avium complex (MAC) lung disease.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense, including related-party expense | $29.5 million | $16.9 million |
| General and administrative expense | $12.8 million | $4.7 million |
| Operating loss | $42.3 million | $21.6 million |
| Net loss | $41.0 million | $21.5 million |
| Operating cash used | $33.5 million | $20.5 million |
- R&D spending increased by $12.6 million, principally due to clinical-trial costs, higher headcount, and outside services. G&A increased by $8.1 million, primarily from personnel, insurance, public-company costs, and external services.
- At December 31, 2022, cash and cash equivalents were $27.2 million; short- and long-term investments were $72.1 million; total assets were $102.6 million; and current liabilities were $7.2 million. The filing reports no debt balance.
- Management stated that available cash, cash equivalents, and investments would fund its current plan for at least 12 months from the filing’s issuance. The filing also emphasizes that substantial additional financing will be needed.
- No meaningful operating margin is applicable given the absence of revenue. Net loss attributable to common stockholders was $42.8 million, or $2.79 per share, in 2022; the 2021 figures were $28.1 million, or $10.64 per share. The per-share comparison is affected by the 2022 IPO and share-count changes.
Material changes versus the prior period
- Net loss rose 90% year over year; operating expenses increased 96%.
- Operating cash use rose from $20.5 million to $33.5 million. Cash provided by financing was $70.4 million in 2022, primarily from the IPO, versus $78.5 million in 2021, primarily from preferred-stock financing.
- The March–April 2022 IPO generated approximately $70.4 million in net proceeds. All outstanding redeemable convertible preferred stock converted into common stock immediately before the IPO.
- Interest income rose to $1.4 million from $0.1 million, partly offsetting the higher net loss.
Outlook, commentary, risks, and unusual items
- Management expected Phase 2 enrollment in the pivotal trial to finish in mid-2023, with Phase 3 enrollment to begin immediately thereafter. It expected top-line results about nine months after enrollment completion for each portion. These are filing-date expectations, not current guidance.
- The trial was planned to enroll about 80 patients in Phase 2 and approximately 234 in Phase 3, subject to changes informed by Phase 2. The company reported nearly 60 sites activated and was enrolling in the United States, Japan, Australia, and South Korea.
- Epetraborole had FDA Fast Track, Qualified Infectious Disease Product, and U.S. orphan designations, as well as European orphan medicinal product designation. Designations do not assure approval or a faster review.
- A September 2022 NIAID cost-reimbursement contract made up to $17.8 million available for development of epetraborole for melioidosis and other biothreat pathogens; $4.3 million was committed for the 18-month base period. No contract income was recognized in 2022.
- Key risks include clinical efficacy and safety uncertainty, patient enrollment and trial-design risks, potential bacterial resistance, long-term safety (the planned trial dosing duration was up to 16 months versus prior human dosing of up to 28 days), dependence on third-party manufacturers and CROs, and the need for additional capital. Prior GSK development included observed clinical resistance in a different infection setting.
- The company reported material weaknesses in financial-reporting controls and concluded disclosure controls were ineffective as of year-end. Remediation included hiring, formalizing controls, and upgrading accounting systems; full remediation could extend beyond December 31, 2023. The auditor gave an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
- After year-end, Silicon Valley Bank was closed in March 2023. AN2 said it held no material cash or cash equivalents there as of March 29, 2023 and did not expect a material impact. The filing also notes inflation, supply-chain and labor pressures, interest-rate uncertainty, and geopolitical risks.
- One MD&A passage states year-end cash, cash equivalents, and investments of $96.1 million, while the audited balance sheet and other disclosures support approximately $99.3 million. The filing text does not explain this difference; verify the correct figure against the financial statements and any subsequent filings.
Important facts for investors to verify
- Current cash, investment balances, burn rate, and financing runway; reconcile the $96.1 million versus approximately $99.3 million liquidity disclosures.
- Actual Phase 2/3 enrollment progress, endpoints, sample size, timing, and results versus the filing-date plan.
- Safety findings from longer-duration dosing, including hematologic effects, and any evidence of resistance or treatment discontinuation.
- Whether NIAID contract options are exercised and reimbursements are received; the maximum award is not guaranteed funding.
- Progress in remediating material weaknesses and any changes to financial controls or reporting.
- Development and commercial rights, royalty and milestone obligations, and patent protection for epetraborole, including the disclosed June 2028 patent expiration date.